We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RSSS:NASDAQResearch Solutions, Inc Analysis

Data as of 2026-06-13 - not real-time

$2.33

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: RSSS trades at $2.33, below its 20‑day, 50‑day and 200‑day moving averages (2.23, 2.40, 2.81), signaling a bearish price trend. The RSI sits at 51.7, indicating a neutral momentum, while the MACD line has just crossed above its signal line, giving a modest bullish hint. Volume is on a decreasing trajectory and 30‑day volatility is high at 68%, suggesting fragile short‑term price stability. Valuation signals: The forward P/E of ~15.2 is well under the industry average of 36.8, but the DCF‑derived fair value ($2.17) is below the current price, hinting at a slight overvaluation on a cash‑flow basis. The market’s “Extreme Greed” sentiment (fear‑greed index 89.86) may be inflating the price beyond fundamentals.
Fundamental backdrop: Revenue slipped 4.3% YoY to $48.7 M, yet subscription revenue rose 7% and gross margin improved to 51.7%, reflecting better pricing power and cost control. Net income turned positive at $860 k and adjusted EBITDA grew 14%, while ROE is a robust 29.8% and the balance sheet is debt‑free with $12 M cash. ARR expanded 8.5% to $22.1 M, underscoring recurring‑revenue momentum. Despite these strengths, B2B churn remains a drag, and the stock’s upside potential is sizable (target median $4.00, ~70% upside).

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below all major moving averages
  • Decreasing volume and high short‑term volatility
  • Neutral RSI and modest MACD bullish crossover

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong margin expansion and positive EBITDA growth
  • ARR increase of 8.5% and subscription revenue up 7%
  • Undervalued relative to industry P/E and sizable upside to target price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE (~30%) and debt‑free balance sheet
  • Growing recurring‑revenue base and AI‑enhanced product roadmap
  • Long‑term upside potential despite current revenue contraction

Key Metrics & Analysis

Financial Health

Revenue Growth-4.30%
Profit Margin9.28%
P/E Ratio15.5
ROE29.82%
ROA5.42%
P/B Ratio4.3
Op. Cash Flow$5.8M
Free Cash Flow$4.6M
Industry P/E36.8

Technical Analysis

TrendBearish
RSI51.7
Support$2.00
Resistance$2.45
MA 20$2.23
MA 50$2.40
MA 200$2.81
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value$2.17
Target Price$3.83
Upside/Downside64.52%
GradeFair
TypeBlend

Risk Assessment

Beta0.71
Volatility68.07%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.